Innavasc
Durham, US · Founded 2013 · 2 known investors
InnAVasc develops a vascular access graft for hemodialysis, featuring self-sealing pods and puncture-resistant backplates that guide dialysis needle placement to reduce needle-injury and bleeding complications. The product targets patients requiring hemodialysis access.
Founders & leadership
Innavasc was founded in 2013 by Shawn Gage and Jeffrey Lawson.
SG
Shawn GageCo-founder
JL
Jeffrey LawsonCo-founder
JK
Joseph KnightExecutive
RD
Roberto Duane MansonNamed on SEC filing
Board
DB
Dani BolognesiBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$4.6M disclosed across 5 rounds · 2016–2021
▶$1MraisedNov 2021 · 41 investors · BiotechnologyRule 506(b)
▶$1MraisedNov 2021 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- C. Steven DunckerDirector
- Craig NicholsExecutive Officer
- William N, StarlingDirector
- Greg DavisDirector
- Joseph KnightExecutive Officer, Director
- Kenneth GallDirector
- Jeffrey LawsonDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Nov 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$414.5KraisedApr 2020 · 20 investors · BiotechnologyRule 506(b)
▶$414.5KraisedApr 2020 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- C Steven DunckerDirector
- William N StarlingDirector
- Greg DavisDirector
- Kenneth GallDirector
- Joseph KnightExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $414.5K
- First sale
- Apr 2020
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$500KraisedOct 2018 · 17 investors · BiotechnologyRule 506(b)
▶$500KraisedOct 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Greg DavisDirector
- William Starling,Jr.Director
- Craig NicholsExecutive Officer
- Stephen DunckerDirector
- Kenneth GallDirector
- Joseph KnightExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Oct 2018
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$2.1MraisedNov 2016 · 39 investors · BiotechnologyRule 506(b)
▶$2.1MraisedNov 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn GageExecutive Officer
- Dani BolognesiDirector
- Jeffrey LawsonExecutive Officer, Director
- Joseph KnightExecutive Officer, Director
- Roberto Duane MansonExecutive Officer
- Offering amount
- $3.3M
- Amount sold
- $2.1M
- First sale
- Oct 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
▶$520KraisedApr 2016 · 14 investors · BiotechnologyRule 506(b)
▶$520KraisedApr 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey LawsonExecutive Officer, Director
- Joseph KnightExecutive Officer, Director
- Roberto MansonExecutive Officer
- Shawn GageExecutive Officer
- Dani BolognesiDirector
- Offering amount
- $1M
- Amount sold
- $520K
- First sale
- Apr 2016
- Incorporated
- Corporation, North Carolina, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Rf Surgical7 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
NeuroVasc7 shared keywordsNeuroVasc Technologies develops catheter-based medical devices designed to treat stroke and other neurological conditions. The company serves patients and healthcare providers requiring neurovascular interventions.
Vantis Vascular5 shared keywordsVantis Vascular develops vascular intervention technology, including the CrossFast integrated vascular delivery system with an auto-locking inner monorail microcatheter and outer delivery catheter for complex PCI procedures. Founded by physicians, the company is also developing next-generation intravascular lithotripsy (IVL) and peripheral below-the-knee (BTK) solutions for vascular interventionalists.</parameter>
<parameter name="founders">[{"full_name": "Jason Turner", "title": "Chief Executive Officer"}, {"full_name": "Tim Fischell", "title": "Chief Medical Officer"}, {"full_name": "Frank Saltiel", "title": "Chief Clinical Officer"}, {"full_name": "Gary McCord", "title": "Chief Commercial Officer"}, {"full_name": "Mike Mirizzi", "title": "Chief Technology Officer"}, {"full_name": "Marc Monahan", "title": "Chief Financial Officer"}]</parameter>
<parameter name="hq_city">San Jose
Innova Vascular5 shared keywordsInnova Vascular is a medical device company focused on the vascular space, led by a founder with a background in developing and commercializing vascular medical devices. The page provides limited detail about the company's specific products.
Access Vascular4 shared keywordsAccess Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.
Imperative Care Inc4 shared keywordsImperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey. The company focuses on devices and solutions for patients suffering from devastating vascular conditions.
AngioDynamics3 shared keywordsAngioDynamics develops and manufactures medical devices aimed at treating serious diseases and improving patient outcomes. Founded in 1988, the company serves healthcare professionals and operates globally across North America, Europe, the Middle East, and South America.
Read the Press Release3 shared keywordsStryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers. It operates globally across the Americas, Europe, Asia-Pacific, and the Middle East.
Companies competing with Innavasc for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Science Foundation | Phase II | 2020 | $749.9K |
| National Science Foundation | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Innavasc do?
- InnAVasc develops a vascular access graft for hemodialysis, featuring self-sealing pods and puncture-resistant backplates that guide dialysis needle placement to reduce needle-injury and bleeding complications. The product targets patients requiring hemodialysis access.
- Who founded Innavasc?
- Innavasc was founded by Shawn Gage, Jeffrey Lawson in 2013.
- Who are Innavasc's investors?
- Innavasc's investors include Duke Capital Partners, Hatteras Venture Partners.
- How much funding has Innavasc raised?
- Innavasc has disclosed $4.6M raised across 5 rounds.
- Where is Innavasc headquartered?
- Innavasc is headquartered in Durham, US.